KEYNOTE-365 cohort D: phase 1b/2 study of pembrolizumab plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer

被引：0

作者：

Appleman, Leonard ^{[1
]}

Piulats, Josep ^{[2
]}

Mar, Nataliya ^{[3
]}

Arranz, Jose ^{[4
]}

Joshua, Anthony ^{[5
]}

Mayer, Tina ^{[6
]}

Shore, Neal ^{[7
]}

Wu, Haiyan ^{[8
]}

Schloss, Charles ^{[8
]}

Yu, Evan ^{[9
]}

机构：

[1] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[2] Catalan Canc Inst, Barcelona, Spain

[3] UC Irvine Med Ctr, Orange, CA USA

[4] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[5] St Vincents Hosp Sydney, Sydney, NSW, Australia

[6] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[7] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[8] Merck & Co Inc, Kenilworth, NJ USA

[9] Univ Washington, Seattle, WA 98195 USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P382

引用

页数：2